ClinicalTrials.gov
public full text
Public Domain
ACTolog in Patients With Solid Cancers
cancercell-therapyesophageal-cancergastric-cancerhead-and-neck-squamous-cell-carcinomaimmunotherapynon-small-cell-lung-cancerovarian-cancer
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer#907966
- First in Human Study of M1069 in Advanced Solid Tumors#1170930
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors#918144
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor#1032871
- A Study of MRG003 in Patients With Advanced Solid Tumors#812943
Record · ID 1047966
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive